Quick answer
KRAS was considered undruggable for decades, and even now most KRAS inhibitors target only the G12C variant. A different approach is to make the immune system recognise the mutant peptide. A phase 1 trial led by Zhao Hong at the Cancer Hospital of the Chinese Academy of Medical Sciences tested a TCR-engineered T-cell therapy restricted to KRAS G12V presented by HLA-A*11:01, in eight patients with advanced solid tumours [1][3].
Key takeaways
- Target: KRAS G12V peptide presented by HLA-A*11:01, an HLA type common in East Asian populations [1][2].
- Design: single-centre, open-label, single-arm, dose-escalation phase 1 [2].
- Eight patients with KRAS G12V-positive advanced solid tumours [3].
- Reported at ASCO 2026 and published as a meeting abstract in the Journal of Clinical Oncology [1].
- Safety was manageable; the study defined a dose for further development [3].
Why TCR-T rather than a pill
CAR-T recognises proteins on the cell surface. Most cancer drivers, including mutant KRAS, sit inside the cell — invisible to an antibody-based receptor. TCR-T solves this by using a T-cell receptor that recognises a fragment of the intracellular protein displayed on HLA molecules on the surface, effectively letting the immune system see inside the cell [2][4].
The catch is that the approach is HLA-restricted — a patient must carry both the mutation and the right HLA type — and engineered T cells must traffic into solid tumours, which are built to exclude them. Both problems limit how many patients can benefit [2][4]. In practice this means TCR-T trials read like precision oncology: sequence the tumour for the mutation, type the HLA, then ask whether the T cells can reach a tumour that excludes immune cells [1][2]. For pancreatic cancer, where the stroma is dense and KRAS mutation is near-universal, the G12V variant is an attractive first target.
What the trial found
The phase 1 study established the safety profile of the infusion and identified a dose for further study. Antitumour activity was observed in some patients, though the numbers are too small for response-rate claims. A second-generation, higher-affinity TCR-T product is now recruiting [1][3].
Dose-escalation phase 1 trials are designed to find a safe dose, not to prove efficacy. With eight participants, any response is a signal rather than a result. The related pancreatic cancer programme reported an objective response rate above 60% in eight patients — encouraging, but again a very small, single-centre series that needs replication [1][5].
The condition in context: KRAS-mutant cancer
KRAS is one of the most commonly mutated oncogenes, and G12V is among its frequent variants.
| Region | What the data shows | Source |
|---|---|---|
| Frequency | KRAS mutations are common in pancreatic, colorectal and lung cancer [4]. | Haihe Cell Ecology Lab [4] |
| Treatment gap | Most KRAS inhibitors target G12C; G12V has fewer options [1]. | PharmCube [1] |
| Solid-tumour CAR-T | CAR-T response rates in solid tumours are about 10–30%, versus 80–90% in blood cancers [4]. | Haihe Cell Ecology Lab [4] |
Because KRAS G12V is present in a substantial minority of pancreatic and lung cancers, a working TCR-T would address a real unmet need [1][4].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| New target class | Intracellular drivers become visible to T cells [2]. | [2] |
| Local capability | A Chinese-developed TCR-T reaching ASCO [1]. | [1] |
| Caution | Eight patients; HLA-restricted; solid-tumour barriers [3][4]. | [3][4] |
Availability and limits
- This is an editorial summary of conference and journal material, not a treatment offer [1][2].
- The therapy is investigational [3].
- Eligibility requires KRAS G12V mutation and HLA-A*11:01 [1].
- Only eight patients were treated; efficacy is unproven [3].
- Manufacturing and cost are major barriers for TCR-T [4].
What to ask before booking
| Question | Why it matters |
|---|---|
| Does my tumour carry KRAS G12V, and am I HLA-A*11:01? | Both are required for eligibility [1]. |
| Are trials recruiting, and what does lymphodepletion involve? | TCR-T requires conditioning chemotherapy [2]. |
| Which department handles foreign patients, and in what language? | The Cancer Hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| What are the risks of cytokine release and neurotoxicity? | These are the main early risks of engineered T cells [3]. |
Questions patients ask
What did the trial test?
A TCR-engineered T-cell therapy targeting the KRAS G12V peptide presented by HLA-A*11:01, in eight patients with advanced solid tumours [1][3].
Why use TCR-T?
Mutant KRAS is intracellular, so CAR-T cannot see it; TCR-T recognises HLA-presented fragments of intracellular proteins [2][4].
What were the results?
The phase 1 established a safe dose and showed early antitumour activity; eight patients is too few to claim a response rate [3].
Who can be treated?
Only patients whose tumours carry KRAS G12V and who are HLA-A*11:01 positive [1].
Is this relevant to international patients?
It is useful context for China's cell therapy research. The Cancer Hospital is a working hospital we do not book — contact it directly [1].